SG11202105992SA - Anticancer compounds - Google Patents

Anticancer compounds

Info

Publication number
SG11202105992SA
SG11202105992SA SG11202105992SA SG11202105992SA SG11202105992SA SG 11202105992S A SG11202105992S A SG 11202105992SA SG 11202105992S A SG11202105992S A SG 11202105992SA SG 11202105992S A SG11202105992S A SG 11202105992SA SG 11202105992S A SG11202105992S A SG 11202105992SA
Authority
SG
Singapore
Prior art keywords
substituted
unsubstituted
group
substituents
alkyl
Prior art date
Application number
SG11202105992SA
Other languages
English (en)
Inventor
López María Jesús Martín
Acebes Raquel Rodríguez
López Patricia Gema Cruz
Solloso Andrés M Francesch
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of SG11202105992SA publication Critical patent/SG11202105992SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SG11202105992SA 2018-12-17 2019-12-17 Anticancer compounds SG11202105992SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382934 2018-12-17
PCT/EP2019/085544 WO2020127194A1 (fr) 2018-12-17 2019-12-17 Composés anticancéreux

Publications (1)

Publication Number Publication Date
SG11202105992SA true SG11202105992SA (en) 2021-07-29

Family

ID=64746491

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105992SA SG11202105992SA (en) 2018-12-17 2019-12-17 Anticancer compounds

Country Status (38)

Country Link
US (1) US12215100B2 (fr)
EP (1) EP3898613B1 (fr)
JP (1) JP7525493B2 (fr)
KR (1) KR20210104791A (fr)
CN (1) CN113166102B (fr)
AR (1) AR116911A1 (fr)
AU (1) AU2019400736B2 (fr)
BR (1) BR112021011304A2 (fr)
CA (1) CA3123744A1 (fr)
CL (1) CL2021001584A1 (fr)
CO (1) CO2021009339A2 (fr)
DK (1) DK3898613T3 (fr)
EA (1) EA202191714A1 (fr)
EC (1) ECSP21050732A (fr)
ES (1) ES2961370T3 (fr)
FI (1) FI3898613T3 (fr)
HR (1) HRP20231286T1 (fr)
HU (1) HUE064529T2 (fr)
IL (1) IL284011B2 (fr)
JO (1) JOP20210139B1 (fr)
LT (1) LT3898613T (fr)
MA (1) MA54520B1 (fr)
MD (1) MD3898613T2 (fr)
MX (1) MX2021007276A (fr)
MY (1) MY203839A (fr)
PH (1) PH12021551438A1 (fr)
PL (1) PL3898613T3 (fr)
PT (1) PT3898613T (fr)
PY (1) PY19105549A (fr)
RS (1) RS64727B1 (fr)
SG (1) SG11202105992SA (fr)
SI (1) SI3898613T1 (fr)
SM (1) SMT202300363T1 (fr)
TW (1) TWI830837B (fr)
UA (1) UA129055C2 (fr)
UY (1) UY38516A (fr)
WO (1) WO2020127194A1 (fr)
ZA (1) ZA202104675B (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR320701A0 (en) 2001-02-20 2001-03-15 Kim, Jonghee The new cancer therapeutic agent with a thiopeptides
WO2005014537A2 (fr) 2003-08-08 2005-02-17 Merck & Co., Inc. Heteroaryles cyclopentyles heterocycliques tetrahydropyrans utilises comme modulateurs de l'activite du recepteur de la chimiokine
GB0523098D0 (en) * 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物

Also Published As

Publication number Publication date
CA3123744A1 (fr) 2020-06-25
PY19105549A (es) 2020-10-02
BR112021011304A2 (pt) 2021-08-31
JOP20210139B1 (ar) 2024-12-22
AR116911A1 (es) 2021-06-23
IL284011B2 (en) 2024-12-01
FI3898613T3 (fi) 2023-11-02
MX2021007276A (es) 2021-07-15
WO2020127194A1 (fr) 2020-06-25
UA129055C2 (uk) 2025-01-01
RS64727B1 (sr) 2023-11-30
HRP20231286T1 (hr) 2024-02-02
US20220056021A1 (en) 2022-02-24
AU2019400736A1 (en) 2021-07-22
LT3898613T (lt) 2023-09-25
CN113166102A (zh) 2021-07-23
MA54520A (fr) 2022-03-23
EA202191714A1 (ru) 2022-03-05
KR20210104791A (ko) 2021-08-25
AU2019400736B2 (en) 2024-12-19
PL3898613T3 (pl) 2023-12-27
CL2021001584A1 (es) 2021-11-26
CO2021009339A2 (es) 2021-09-30
HUE064529T2 (hu) 2024-04-28
JP7525493B2 (ja) 2024-07-30
PT3898613T (pt) 2023-10-17
PH12021551438A1 (en) 2021-12-06
JOP20210139A1 (ar) 2023-01-30
ZA202104675B (en) 2023-12-20
TWI830837B (zh) 2024-02-01
IL284011A (en) 2021-08-31
EP3898613A1 (fr) 2021-10-27
IL284011B1 (en) 2024-08-01
ES2961370T3 (es) 2024-03-11
SMT202300363T1 (it) 2023-11-13
CN113166102B (zh) 2025-08-08
UY38516A (es) 2020-07-31
DK3898613T3 (da) 2023-11-13
TW202039475A (zh) 2020-11-01
MA54520B1 (fr) 2023-09-27
JP2022513268A (ja) 2022-02-07
MD3898613T2 (ro) 2023-12-31
US12215100B2 (en) 2025-02-04
EP3898613B1 (fr) 2023-08-09
ECSP21050732A (es) 2021-08-31
SI3898613T1 (sl) 2023-12-29
MY203839A (en) 2024-07-20

Similar Documents

Publication Publication Date Title
AU2022200249C1 (en) Antitumoral Compounds
CA2800097C (fr) Procede synthetique de fabrication de composes d'exteinascidine et d'intermediaires
EP4527415A1 (fr) Conjugué anticorps-médicament contenant un composé bioactif d'agent de dégradation de protéine, son procédé de préparation et son utilisation
CA3006247A1 (fr) Conjugues comprenant des groupes peptidiques et procedes associes a ceux-ci
CZ304204B6 (cs) Deriváty aplidinu
US11512096B2 (en) Seco macrolide compounds
JPH0977791A (ja) ペプチド誘導体及びその用途
CA2708080C (fr) Composes antitumoraux
AU2019400736B2 (en) Anticancer compounds
HK40055523B (en) Anticancer compounds
HK40055523A (en) Anticancer compounds
EA048678B1 (ru) Противораковые соединения
CA3024324C (fr) Composes macrolides de type seco